Literature DB >> 35990391

Injection Site Pain, Onset and Duration of Action of Botulinum Toxin Reconstituted in Normal Saline With and Without Sodium Bicarbonate: A Prospective, Single Center, Randomized, Double-Blind Interventional Study.

Yazeed Alghonaim1, Leen O Hijazi2, Sondus A Alraee2, Yasser Alqubaisy3.   

Abstract

Purpose: This study was designed to investigate the effects of botulinum toxin type A injections diluted with the mixture of sodium bicarbonate and normal saline on pain reduction, onset of action, and duration of action.
Methods: This is a prospective, randomized, double-blind clinical study, which included 30 female patients (age >25). The patients were randomized to receive botulinum toxin injections diluted with normal saline and sodium bicarbonate on one side of the face and saline control injections on the other side. Pain severity was assessed using visual analogue scale. The onset and duration of action were recorded according to the patients' subjective opinions after 1 week and 3 months, respectively.
Results: Lower pain intensity ratings were observed when botulinum toxin was diluted with 0.05 and 0.1 mL of sodium bicarbonate as compared to saline. Regarding the onset of action, the botulinum toxin injections diluted with saline and 0.1-mL sodium bicarbonate side showed faster response in many patients than other dilutions (P < .001). Both the 0.05-mL and 0.1-mL sodium bicarbonate concentrations showed longer duration effects on patients than other concentrations.
Conclusion: The use of sodium bicarbonate and saline in a mixture for the dilution of botulinum toxin can decrease patients' discomfort and provide a faster action with longer duration effects.
© 2021 The Author(s).

Entities:  

Keywords:  botulinum toxin; sodium bicarbonate; wrinkles

Year:  2021        PMID: 35990391      PMCID: PMC9389062          DOI: 10.1177/22925503211011971

Source DB:  PubMed          Journal:  Plast Surg (Oakv)        ISSN: 2292-5503            Impact factor:   0.558


  13 in total

Review 1.  Treatment of hyperhidrosis with botulinum toxin.

Authors:  Richard G Glogau
Journal:  Dermatol Clin       Date:  2004-04       Impact factor: 3.478

2.  Easing Botox administration with EMLA cream.

Authors:  Barry L Eppley
Journal:  Aesthet Surg J       Date:  2004 Jan-Feb       Impact factor: 4.283

3.  Pain sensation during intradermal injections of three different botulinum toxin preparations in different doses and dilutions.

Authors:  Gottfried Kranz; Thomas Sycha; Bernhard Voller; Andreas Gleiss; Peter Schnider; Eduard Auff
Journal:  Dermatol Surg       Date:  2006-07       Impact factor: 3.398

4.  Botulinum toxin therapy: reduction of injection site pain by pH normalisation.

Authors:  Dirk Dressler; Fereshte Adib Saberi; Hans Bigalke
Journal:  J Neural Transm (Vienna)       Date:  2016-03-22       Impact factor: 3.575

5.  A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis.

Authors:  P Schnider; M Binder; H Kittler; P Birner; D Starkel; K Wolff; E Auff
Journal:  Br J Dermatol       Date:  1999-04       Impact factor: 9.302

6.  Botulinum toxin type B: pH change reduces injection pain, retains efficacy.

Authors:  Philippa L Lowe; Nicholas J Lowe
Journal:  Dermatol Surg       Date:  2014-12       Impact factor: 3.398

7.  Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial.

Authors:  Murad Alam; Jeffrey S Dover; Kenneth A Arndt
Journal:  Arch Dermatol       Date:  2002-04

Review 8.  Botulinum toxin injection for facial wrinkles.

Authors:  Rebecca Small
Journal:  Am Fam Physician       Date:  2014-08-01       Impact factor: 3.292

9.  Botulinum toxins for facial lines: a concise review.

Authors:  Nicholas J Lowe; Philippa Lowe
Journal:  Dermatol Ther (Heidelb)       Date:  2012-09-29

10.  Trends and demographic characteristics of Saudi cosmetic surgery patients.

Authors:  Sami E Alharethy
Journal:  Saudi Med J       Date:  2017-07       Impact factor: 1.484

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.